CHOC Children's is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Mark Daniels, MD, the TrialNet team at CHOC Children's is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Dr. Mark Daniels has served as Principal Investigator for the TrialNet studies conducted here at CHOC. He has been board certified in pediatric endocrinology since 2003 after completing his medical school training, residency and pediatric endocrinology fellowship at Stanford University
Heather Speer CCRC MPH CHES CDE has been a very active and effective research coordinator in the Diabetes Prevention Trial-Type 1 and TrialNet. She is dedicated to recruiting study subjects for all the studies through excellent networking relationships with the TrialNet personnel and local physicians, support groups, health care personnel, and outreach community fairs.
If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More
Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More
We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D. Details
TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 or stage 2), and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression. Details
If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More